Customer Spotlight: Amgen on the Berkeley Lights Platform
Philip Tagari, VP Therapeutic Discovery, Amgen, discusses how the Berkeley Lights’ platform has transformed the way Amgen approaches antibody discovery and cell line development.
App Note: Bring Product Quality Assessment into Early Clone Selection with the Opto™ Assure Aggregation Assay
Read this application note to learn more about how to get early, multi-parameter assessment of clones with the Opto Assure assay series.
Brochure: Get to Market Faster with the Opto CLD Workflow
Find out how the Opto CLD workflow sets a new standard for quality, capacity, and speed in cell line development to let BioPharma get more molecules to the clinic faster.
Brochure: Increase CDMO Revenue with the Opto CLD Workflow
Find our how the Opto CLD workflow sets a new standard for quality, capacity, and speed in cell line development and allows CDMOs to scale operations and drive new business.
Webinar: Leveraging Innovative Technologies to Accelerate Biologics Development
At the 2021 BPS EU virtual conference, Beacon user Joaquina Mascarenhas, PhD, at Thermo Fisher Scientific shares how the Berkeley Lights Platform enables their cell line development to move at world class speed and select the best clones.
Webinar: Accelerating Discovery and Development of Antibody Therapeutics
Hear from BLI experts Renee Tobias and Anupam Singhal about the unique benefits to leveraging a single platform for both the identification of promising candidates and the production of leading therapeutic molecules.
App Note: FDA-Accepted Monoclonality Assurance on the Beacon® Optofluidic System for Cell Line Development
Learn how the Beacon system’s superior cloning technology, automated imaging capabilities, and in-process quality controls provide definitive evidence of monoclonality to support regulatory approvals.
Webinar: Get More Molecules to The Clinic Faster
Watch our presentation from BPI Digital Week, hosted by Renee Tobias, to hear how our customers are using the Opto™ CLD workflow to find the best cell lines with the most confident monoclonality in just a few day and de-risk their path to IND faster.
Customer Spotlight: Amgen on AbD and CLD
Find out how Amgen is transforming their antibody discovery and clonal cell line processes with the Berkeley Lights Platform.
Fireside Chat: Every Day Matters – Optimizing COVID-19 Therapies for Manufacturing
Dr. James Rothman, Nobel Laureate hosts an in-depth discussion with distinguished guests, Dr. Jennitte Stevens from Amgen, Dr. Gregory Bleck from Catalent-Biologics, and Dr. Trent Munro from the University of Queensland on fast-tracking the development of therapeutic antibodies and vaccines for SARS-CoV-2.
Customer Spotlight: Catalent on CLD
Find out how Catalent Biologics is able to select significantly higher expressing clonal cell lines with the Opto CLD workflow.
Product Tour: The Opto™ CLD Workflow
Antibody expert, Anupam Singhal, PhD, does a 10-minute walkthrough of how the Opto™ CLD workflow makes it possible to produce superior cell lines, with >99% monoclonality assurance, in a matter of days.
Poster: Rapid Generation of Production Cell Lines with Superior Titers and >99% Monoclonality for Complex Antibody Molecules
See how the Opto CLD 2.0 Workflow enables rapid generation of cell lines secreting antibodies for both traditional and non-traditional antibodies while acquiring a superior data package.
Datasheet: Opto™ CLD 2.0 Workflow
Overview of the Opto CLD 2.0 workflow and representative results.
Cell Line Development Webinar: Digital Week 2019
Learn about improved and expedited cell line development on the Beacon platform from Biogen’s Rachel Ferguson.
Webinar: BPI Digital Week 2018
Watch a 1-hour webinar from the 2018 BioProcess International Digital Week titled, “Implementing the Beacon Platform for the Next Generation of Cell Line Development,” featuring scientists from Berkeley Lights and Catalent Biologics.